JMI

EQS-News: Element unveils fully integrated pharma services platform, strengthening its expanding Life Sciences Division

Retrieved on: 
Tuesday, September 5, 2023

Element unveils fully integrated pharma services platform, strengthening its expanding Life Sciences Division

Key Points: 
  • Element unveils fully integrated pharma services platform, strengthening its expanding Life Sciences Division
    The issuer is solely responsible for the content of this announcement.
  • Element unveils fully integrated pharma services platform, strengthening its expanding Life Sciences Division
    05 September 2023 – Element Materials Technology (Element), a leading global Testing, Inspection and Certification (TIC) company, has launched an integrated offering for its pharmaceutical services.
  • With the unveiling of our integrated pharmaceutical services platform, Element Life Sciences now stands ready to address these challenges head-on.
  • Element Life Sciences stands as a steadfast partner, empowering pharmaceutical companies to overcome obstacles and advance their groundbreaking innovations in the dynamic and ever-evolving landscape of the life sciences industry.

Venatorx Pharmaceuticals Highlights Two Recent Publications Indicating Rising Metallo-Beta-Lactamases for Carbapenem-Resistant Enterobacterales in US

Retrieved on: 
Monday, August 14, 2023

When looking deeper at the specific contribution from carbapenemase families, metallo-beta-lactamases (MBLs) were the most frequently identified carbapenem resistance mechanism.

Key Points: 
  • When looking deeper at the specific contribution from carbapenemase families, metallo-beta-lactamases (MBLs) were the most frequently identified carbapenem resistance mechanism.
  • In the U.S. and Canada, MBLs were found in 15.5% of all CRE isolates in 2018-2019, or approximately 1 out of every 7 CRE isolates.
  • This represents a 300% increase from the 2012-17 period when only 5% of CRE isolates expressed MBLs in the US and Canada.
  • [4] of Johns Hopkins University analyzed consecutive CRE clinical isolates collected from unique patients at 3 US hospitals from 2016-2021.

JMI Equity Announces Promotions

Retrieved on: 
Tuesday, August 1, 2023

JMI Equity (“JMI”), a growth equity firm focused on investing in leading software companies, today announced the promotions of Lindsay Mehta to Director, Investor Relations & Marketing, and Christian Kurth to Principal.

Key Points: 
  • JMI Equity (“JMI”), a growth equity firm focused on investing in leading software companies, today announced the promotions of Lindsay Mehta to Director, Investor Relations & Marketing, and Christian Kurth to Principal.
  • View the full release here: https://www.businesswire.com/news/home/20230801752781/en/
    In addition, JMI announced the promotions of Dina Berdichevsky and Josh Wang to Vice President.
  • “These well-deserved promotions are a testament to the talent of our team and the professional development that JMI actively supports throughout our colleagues’ careers,” said Peter Arrowsmith, Managing General Partner at JMI.
  • Prior to joining JMI in 2015, Kurth was an investment banking analyst in the technology group at Wells Fargo.

GrowthCap Announces The Top 25 Healthcare Investors of 2023

Retrieved on: 
Tuesday, May 23, 2023

NEW YORK, May 23, 2023 /PRNewswire-PRWeb/ -- GrowthCap is pleased to announce The Top 25 Healthcare Investors of 2023. Our third year running, the healthcare awards process has become more competitive not only in the number of participants but also in the caliber of individuals put forth. We are inspired by the dedication of this year's awardees toward their craft and towards solving some of the healthcare industry's most pressing challenges. These investors have highly specialized knowledge, are keenly aware of sub-sector areas to focus on, work effectively with management teams, and operate strategically to consistently produce successful outcomes.

Key Points: 
  • This year's awardees are the top healthcare investors who have demonstrated the attributes to sustain a high level of investment performance - past, present and future.
  • NEW YORK, May 23, 2023 /PRNewswire-PRWeb/ -- GrowthCap is pleased to announce The Top 25 Healthcare Investors of 2023.
  • We are inspired by the dedication of this year's awardees toward their craft and towards solving some of the healthcare industry's most pressing challenges.
  • Please join us in recognizing and celebrating the achievements of The Top 25 Healthcare Investors of 2023.

Huntress Secures $60 Million Series C Funding to Expand Suite of Solutions that Protect SMBs from Cyber Attacks

Retrieved on: 
Tuesday, May 16, 2023

Sapphire Partner Casber Wang will join the Huntress board of directors, along with Operating Partner Mahau Ma as a board observer.

Key Points: 
  • Sapphire Partner Casber Wang will join the Huntress board of directors, along with Operating Partner Mahau Ma as a board observer.
  • We're thrilled to be part of the Huntress journey and partner on their mission to protect SMBs – the backbone of the global economy."
  • Huntress Expands Platform and Customer Base, Delivering Comprehensive Protection to SMBs
    This funding will fuel enhancements to Huntress’ Managed Security Platform, and the company’s market expansion.
  • “Huntress is at an exciting stage, addressing a critical need for businesses in the face of increasing risk of cyber attacks,” said Ma.

UPDATE: Indoor Harvest Corp. Expands its Portfolio with the Acquisition of 60% Controlling Interest in Metabiogenix USA®

Retrieved on: 
Monday, May 8, 2023

During the close of the acquisition, Metabiogenix USA® received a valuation of $8.9M USD from the Japanese Medical Institute (JMI).

Key Points: 
  • During the close of the acquisition, Metabiogenix USA® received a valuation of $8.9M USD from the Japanese Medical Institute (JMI).
  • “This acquisition will provide Indoor Harvest an exclusive agreement to market and distribute the portfolio of Metabiogenix USA® Nutraceuticals throughout the entire Western Hemisphere (North, South, and Central America), and Spain.
  • “I am honored to join the Indoor Harvest family and looking forward to leading Metabiogenix USA® and educating the world about “The Metabolism of Life!”.
  • As part of the acquisition, Dr. Acosta will be retained under a new developing employment agreement as President of Metabiogenix USA®.

Indoor Harvest Corp. Expands its Portfolio with the Acquisition of 60% Controlling Interest in Metabiogenix USA®

Retrieved on: 
Monday, May 8, 2023

During the close of the acquisition, Metabiogenix USA® received a valuation of $8.9M USD from the Japanese Medical Institute (JMI).

Key Points: 
  • During the close of the acquisition, Metabiogenix USA® received a valuation of $8.9M USD from the Japanese Medical Institute (JMI).
  • “This acquisition will provide Indoor Harvest an exclusive agreement to market and distribute the portfolio of Metabiogenix USA® Nutraceuticals throughout the entire Western Hemisphere (North, South, and Central America), and Spain.
  • “I am honored to join the Indoor Harvest family and looking forward to leading Metabiogenix USA® and educating the world about “The Metabolism of Life!”.
  • As part of the acquisition, Dr. Acosta will be retained under a new developing employment agreement as President of Metabiogenix USA®.

 Maryland Tech Council Announces 2023 ICON Award Winners

Retrieved on: 
Friday, April 28, 2023

Under Mr. Williams’s leadership, JASINT has grown to 80 employees holding prime contracts with numerous federal entities.

Key Points: 
  • Under Mr. Williams’s leadership, JASINT has grown to 80 employees holding prime contracts with numerous federal entities.
  • SYNAPS Dx is a privately held company focused on the research, development and commercialization of a diagnostic test for Alzheimer’s disease (AD).
  • She is passionate about women’s equality in tech and serves on the board of ITS America.
  • Kite recently announced the expansion of its global cell therapy supply chain operations in Frederick, Maryland that will create 100 additional jobs in the area.

Coursedog Receives $90 Million Strategic Growth Investment from JMI Equity to Accelerate Product Development and Customer Success

Retrieved on: 
Wednesday, March 29, 2023

Coursedog, the leading Academic Operations Platform for higher education, announced today that it has received a $90 million strategic growth investment from JMI Equity (“JMI”), a growth equity firm focused on investing in leading software companies.

Key Points: 
  • Coursedog, the leading Academic Operations Platform for higher education, announced today that it has received a $90 million strategic growth investment from JMI Equity (“JMI”), a growth equity firm focused on investing in leading software companies.
  • Since its founding in 2018 by Columbia University students Justin Wenig and Nicholas Diao, Coursedog has been dedicated to building software that breaks down barriers to opportunity for students.
  • Coursedog’s flagship Academic Operations Platform enables higher education institutions to optimize curriculum planning, course scheduling, event management, and catalog management.
  • “We raised capital to continue to establish Coursedog as a top startup for attracting mission-driven talent and to double down on partner success,” said Justin Wenig, Coursedog Co-Founder and CEO.

JMI Equity Closes Eleventh Growth Equity Fund with Commitments of $2.4 Billion

Retrieved on: 
Monday, March 20, 2023

JMI Equity (“JMI” or the “Firm”), a growth equity firm focused on investing in leading software companies, today announced the closing of JMI Equity Fund XI, L.P. (“JMI XI” or the “Fund”) and JMI XI Executive Fund, L.P. with total commitments of $2.4 billion.

Key Points: 
  • JMI Equity (“JMI” or the “Firm”), a growth equity firm focused on investing in leading software companies, today announced the closing of JMI Equity Fund XI, L.P. (“JMI XI” or the “Fund”) and JMI XI Executive Fund, L.P. with total commitments of $2.4 billion.
  • The Fund was oversubscribed, with demand exceeding the original $2 billion target, and received strong support from new and existing investors.
  • JMI XI brings JMI’s total capital commitments to more than $8 billion since the Firm’s inception in 1992.
  • Proskauer Rose LLP served as legal counsel in the formation of JMI XI.